

2024–2025 COVID-19 Vaccination Guidance

for People 6 Months of Age and Older



These tables provide guidance for the use of COVID-19 vaccines based on age, health status, and product. Start with the person's current age and COVID-19 vaccination history. Use these tables in conjunction with [Clinical Guidance for COVID-19 Vaccination | CDC](#) and the [Immunization Schedules | Vaccines & Immunizations | CDC for children, adolescents and adults](#).

Table 1a. For people who are **NOT** moderately or severely immunocompromised*

2024–25 Moderna COVID-19 Vaccine

Vaccine type: mRNA | Do NOT use any previously available Moderna COVID-19 vaccine products.

| If current age is: | And the COVID-19 vaccination history is: | Then: | Administer: |
|---|---|--|---|
| 6 months through 4 years[†] | Unvaccinated (0 doses) | Give a 2-dose initial series. <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 4–8 weeks after Dose 1.[‡] | 0.25 mL/25 µg in a manufacturer-filled syringe (MFS) |
| | 1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) | Complete the series. <ul style="list-style-type: none"> • Dose 2 at least 4–8 weeks after Dose 1.[‡] | Intramuscular (IM) injection |
| | 2 or more previous doses of any Moderna COVID-19 Vaccine, NOT including 1 dose of 2024–25 Moderna COVID-19 vaccine [§] | Give 1 dose at least 8 weeks after the last dose. | |
| | 2 or more previous doses of any Moderna COVID-19 Vaccine, INCLUDING at least 1 dose of 2024–25 Moderna COVID-19 vaccine [§] | No further doses are indicated. | |
| 5 through 11 years[¶] | Unvaccinated (0 doses) | Give 1 dose now. | 0.25 mL/25 µg in an MFS |
| | Any number of previous doses of any mRNA COVID-19 vaccine, NOT including 1 dose of 2024–25 mRNA COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose. | Intramuscular (IM) injection |
| | Any number of previous doses of any mRNA COVID-19 vaccine, INCLUDING 1 dose of 2024–25 mRNA COVID-19 vaccine | No further doses are indicated. | |

* People with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† Children 6 months through 4 years of age should receive all COVID-19 vaccine doses from the same manufacturer. In the following circumstances, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication. For children who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer: • Dose 2 at least 4–8 weeks after Dose 1. • Dose 3 at least 8 weeks after Dose 2.

‡ An 8-week interval between the first and second doses of Moderna COVID-19 vaccine might be optimal for some people, as it might reduce the small risk of myocarditis and pericarditis associated with COVID-19 vaccines.

§ If the vaccination history includes 1 dose of 2024–25 Pfizer-BioNTech COVID-19 Vaccine, no further doses are indicated.

¶ CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination. For children who turn 5 years of age during the initial series, administer 1 dose of age-appropriate vaccine (**0.25 mL/25 µg**) at least 4–8 weeks after Dose 1. (This is not a dosage change.) No further doses of 2024–25 COVID-19 vaccine are indicated.

2024–2025 COVID-19 Vaccination Guidance

for People 6 Months of Age and Older



Table 1a. For people who are **NOT** moderately or severely immunocompromised* *Continued*

2024–25 Moderna COVID-19 Vaccine

Vaccine type: mRNA | Do NOT use any previously available Moderna COVID-19 vaccine products.

| If current age is: | And the COVID-19 vaccination history is: | Then: | Administer: |
|----------------------------------|---|---|---|
| 12 through 64 years | Unvaccinated (0 doses) | Give 1 dose now. | 0.5 mL/50 µg in an MFS Intramuscular (IM) injection |
| | Any number of previous doses of any COVID-19 vaccine, NOT including 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose. | |
| | Any number of previous doses of COVID-19 vaccine, INCLUDING at least 1 dose of 2024–25 vaccine [†] | No further doses are indicated. | |
| 65 years of age and older | Unvaccinated (0 doses) | Give 1 dose now, followed by 1 dose 6 months later. [‡] | 0.5 mL/50 µg in an MFS Intramuscular (IM) injection |
| | Any number of previous doses of any COVID-19 vaccine, NOT including 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose, followed by 1 dose 6 months later. [‡] | |
| | Any number of previous doses of any COVID-19 vaccine, INCLUDING 1 dose of any 2024–25 COVID-19 vaccine [†] | Give 1 dose 6 months after the last dose of the 2024–25 COVID-19 vaccine. [‡] | |
| | Any number of previous doses of any COVID-19 vaccine, INCLUDING 2 doses of any 2024–25 COVID-19 vaccine [†] | No further doses are indicated. | |

* People with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† If the vaccination history includes 1 or 2 doses of 2024–25 Novavax COVID-19 vaccine, see Table 1c of this document for detailed guidance or CDC's [Clinical Guidance for COVID-19 Vaccination](#) | CDC

‡ May be administered as soon as 8 weeks after the last dose of 2024–25 COVID-19 vaccine.

2024–2025 COVID-19 Vaccination Guidance

for People 6 Months of Age and Older



Table 1b. For people who are **NOT** moderately or severely immunocompromised*

| 2024–25 Pfizer-BioNTech COVID-19 Vaccine | | | |
|---|---|---|---|
| Vaccine type: mRNA Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products. | | | |
| If current age is: | And the COVID-19 vaccination history is: | Then: | Administer: |
| 6 months through 4 years[†] | Unvaccinated (0 doses) | Give a 3-dose initial series. <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 3–8 weeks after Dose 1.[‡] • Dose 3 at least 8 weeks after Dose 2. | 0.3 mL/3 µg from a yellow-capped multidose vial Intramuscular (IM) injection |
| | 1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) | Complete the series. <ul style="list-style-type: none"> • Dose 2 at least 3–8 weeks after Dose 1.[‡] • Dose 3 at least 8 weeks after Dose 2. | |
| | 2 previous doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) | Complete the series. <ul style="list-style-type: none"> • Dose 3 at least 8 weeks after Dose 2. | |
| | 3 or more previous doses of any Pfizer-BioNTech COVID-19 vaccine, NOT including at least 1 dose of 2024–25 Pfizer-BioNTech COVID-19 Vaccine [§] | Give 1 dose at least 8 weeks after the last dose. | |
| | 3 or more previous doses of any Pfizer-BioNTech COVID-19 vaccine, INCLUDING at least 1 dose of 2024–25 Pfizer-BioNTech COVID-19 Vaccine [§] | No further doses are indicated. | |
| 5 through 11 years[¶] | Unvaccinated (0 doses) | Give 1 dose now. | 0.3 mL/10 µg from a blue-capped single-dose vial Intramuscular (IM) injection |
| | Any number of any previous doses of any mRNA COVID-19 vaccine, NOT including 1 dose of 2024–25 mRNA COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose. | |
| | Any number of any previous doses of any mRNA COVID-19 vaccine, INCLUDING 1 dose of 2024–25 mRNA COVID-19 vaccine | No further doses are indicated. | |

* People with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† Children 6 months through 4 years of age should receive all COVID-19 vaccine doses from the same manufacturer. In the following circumstances, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication. For children who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer: • Dose 2 at least 4–8 weeks after Dose 1. • Dose 3 at least 8 weeks after Dose 2.

‡ An 8-week interval between the first and second doses of COVID-19 vaccine might be optimal for some people, as it might reduce the small risk of myocarditis and pericarditis associated with COVID-19 vaccines.

§ If the vaccination history includes 1 dose of 2024–25 Moderna COVID-19 Vaccine, no further doses are indicated.

¶ CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination. For children who turn 5 years of age during the initial series, administer 1 dose of the age-appropriate vaccine (**0.3 mL/10 µg**). If the **10 µg** dose is: • Dose 2: Administer 3–8 weeks after Dose 1. No further doses of 2024–25 COVID-19 vaccine are indicated. • Dose 3: Administer at least 8 weeks after Dose 2. No further doses of 2024–25 COVID-19 vaccine are indicated.

2024–2025 COVID-19 Vaccination Guidance

for People 6 Months of Age and Older



Table 1b. For people who are **NOT** moderately or severely immunocompromised* *Continued*

2024–25 Pfizer-BioNTech COVID-19 Vaccine

Vaccine type: mRNA | Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products.

| If current age is: | And the COVID-19 vaccination history is: | Then: | Administer: |
|-----------------------------------|---|---|--|
| 12 through 64 years of age | Unvaccinated (0 doses) | Give 1 dose now. | 0.3 mL/30 µg in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection |
| | Any number of previous doses of any COVID-19 vaccine, NOT including 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose. | |
| | Any number of previous doses of COVID-19 vaccine, INCLUDING at least 1 dose of 2024–25 COVID-19 vaccine [†] | No further doses are indicated. | |
| 65 years of age and older | Unvaccinated (0 doses) | Give 1 dose now, followed by 1 dose 6 months later. [‡] | 0.3 mL/30 µg in an MFS Intramuscular (IM) injection |
| | Any number of previous doses of any COVID-19 vaccine, NOT including 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose, followed by 1 dose 6 months later. [‡] | |
| | Any number of previous doses of any COVID-19 vaccine, INCLUDING ONLY 1 dose of any 2024–25 COVID-19 vaccine [†] | Give 1 dose 6 months after the last dose of the 2024–25 COVID-19 vaccine. [‡] | |
| | Any number of previous doses of any COVID-19 vaccine, INCLUDING 2 doses of any 2024–25 COVID-19 vaccine [†] | No further doses are indicated. | |

* People with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† If the vaccination history is 1 or 2 doses of 2024–25 Novavax COVID-19 vaccine, see Table 1c of this document for detailed guidance or CDC's [Clinical Guidance for COVID-19 Vaccination](#) | CDC.

‡ May be administered as soon as 8 weeks after the last dose of 2024–25 COVID-19 vaccine.

2024–2025 COVID-19 Vaccination Guidance

for People 6 Months of Age and Older



Table 1c. For people who are **NOT** moderately or severely immunocompromised*

| 2024–25 Novavax COVID-19 Vaccine | | | |
|--|--|--|--|
| Vaccine type: Protein subunit Do NOT use any previously available Novavax COVID-19 vaccine products. | | | |
| If current age is: | And the COVID-19 vaccination history is: | Then: | Administer: [†] |
| 12 through 64 years of age | Unvaccinated (0 doses) | Give a 2-dose initial series. <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 3–8 weeks after Dose 1[‡] | 0.5 mL/5 µg in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection |
| | 1 previous dose of any Novavax COVID-19 Vaccine (Dose 1) | Complete the series. <ul style="list-style-type: none"> • Dose 2 at least 3–8 weeks after Dose 1.[‡] | Intramuscular (IM) injection |
| | 2 previous doses of 2024–25 Novavax COVID-19 Vaccine | No further doses are indicated. | |
| | 2 or more previous doses of any Novavax COVID-19 vaccine, NOT including 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose. | 0.5 mL/5 µg in an MFS Intramuscular (IM) injection |
| | 2 or more previous doses of any Novavax COVID-19 vaccine, INCLUDING 1 dose of any 2024–25 COVID-19 vaccine | No further doses are indicated. | |
| | Any number of previous doses of any mRNA COVID-19 vaccine, NOT including 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose. | 0.5 mL/5 µg in an MFS Intramuscular (IM) injection |
| | Any number of previous doses of any mRNA COVID-19 vaccine, INCLUDING 1 dose of any 2024–25 COVID-19 vaccine | No further doses are indicated. | |

* People with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† Each 0.5 mL dose of Novavax contains 5 µg rS protein and 50 µg Matrix-M adjuvant.

‡ An 8-week interval between the first and second doses of Novavax COVID-19 vaccine might be optimal for some people, as it might reduce the small risk of myocarditis and pericarditis associated with COVID-19 vaccines.

2024–2025 COVID-19 Vaccination Guidance

for People 6 Months of Age and Older



Table 1c. For people who are **NOT** moderately or severely immunocompromised* *Continued*

| 2024–25 Novavax COVID-19 Vaccine | | | |
|---|---|--|--|
| Vaccine type: Protein subunit Do NOT use any previously available Novavax COVID-19 vaccine products. | | | |
| If current age is: | And the COVID-19 vaccination history is: | Then: | Administer: [†] |
| 65 years of age and older | Unvaccinated (0 doses) | Give a 2-dose initial series. <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 3–8 weeks after Dose 1.[‡] Dose 3: Give 6 months after Dose 2. [§] | 0.5 mL/5 µg in an MFS Intramuscular (IM) injection |
| | 1 previous dose of any Novavax COVID-19 Vaccine (Dose 1) | Complete the series. <ul style="list-style-type: none"> • Dose 2 at least 3–8 weeks after the last dose.[‡] Dose 3: Give 6 months after Dose 2. [§] | |
| | 2 previous doses of 2024–25 Novavax COVID-19 Vaccine | Give 1 dose 6 months after the last dose of 2024–25 COVID-19 vaccine. [§] | |
| | 2 or more previous doses of any Novavax COVID-19 vaccine, NOT including 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose, followed by 1 dose 6 months later. [§] | |
| | 2 or more previous doses of any Novavax COVID-19 vaccine, INCLUDING ONLY 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose 6 months after the last dose of the 2024–25 COVID-19 vaccine. [§] | |
| | 3 or more previous doses of any Novavax COVID-19 vaccine, INCLUDING at least 2 doses of any 2024–25 COVID-19 vaccine | No further doses are indicated. | |
| | Any number of previous doses of any mRNA COVID-19 vaccine, NOT including at least 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose, followed by 1 dose 6 months later. [§] | 0.5 mL/5 µg in an MFS Intramuscular (IM) injection |
| | Any number of previous doses of any mRNA COVID-19 vaccine, INCLUDING 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose 6 months after the last dose of the 2024–25 COVID-19 vaccine. [§] | |
| Any number of previous doses of any mRNA COVID-19 vaccine, INCLUDING 2 doses of any 2024–25 COVID-19 vaccine | No further doses are indicated. | | |

* People with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† Each 0.5 mL dose of Novavax contains 5 µg rS protein and 50 µg Matrix-M adjuvant.

‡ An 8-week interval between the first and second doses of Novavax COVID-19 vaccine might be optimal for some people, as it might reduce the small risk of myocarditis and pericarditis associated with COVID-19 vaccines.

§ May be administered as soon as 8 weeks after the last dose of 2024–25 COVID-19 vaccine.

2024–2025 COVID-19 Vaccination Guidance

for People 6 Months of Age and Older



Table 2a. For people who **ARE** moderately or severely immunocompromised

| 2024–25 Moderna COVID-19 Vaccine Vaccine type: mRNA Do NOT use any previously available Moderna COVID-19 vaccine products. | | | |
|---|--|--|---|
| If current age is: | And the COVID-19 vaccination history is: | Then: | Administer: |
| 6 months through 4 years* | Unvaccinated (0 doses) | Give a 3-dose initial series. <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 4 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.† | 0.25 mL/25 µg in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection |
| | 1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) | Complete the series. <ul style="list-style-type: none"> • Dose 2 at least 4 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.† | |
| | 2 previous doses of any Moderna COVID-19 Vaccine (Doses 1 and 2) | Complete the series. <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.† | |
| | 3 or more previous doses of any Moderna COVID-19 Vaccine, NOT including 1 dose of 2024–25 Moderna COVID-19 Vaccine‡ | Give 1 dose at least 8 weeks after the last dose, followed by 1 dose 6 months later.† | |
| | 3 or more previous doses of any Moderna COVID-19 Vaccine, INCLUDING ONLY 1 dose of 2024–25 Moderna COVID-19 Vaccine‡ | Give 1 dose 6 months after the last dose of 2024–25 COVID-19 vaccine.† | |
| | 4 or more previous doses of any Moderna COVID-19 Vaccine, INCLUDING at least 2 doses of 2024–25 Moderna COVID-19 Vaccine‡ | Additional dose(s) may be given using shared clinical decision-making at least 8 weeks after last dose of 2024–25 COVID-19 vaccine.§ | |

* Children 6 months through 4 years of age who are moderately to severely immunocompromised should receive all COVID-19 vaccine doses from the same manufacturer. In the following circumstances, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication. If mRNA vaccines are administered from different manufacturers, a 3-dose initial series should be followed:

- Children who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:
 - Dose 2 at least 4 weeks after Dose 1.
 - Dose 3 at least 8 weeks after Dose 2.
- Children who received 2 doses of vaccine from different manufacturers, administer Dose 3 at least 8 weeks after Dose 2.

† May be administered as soon as 8 weeks after the last dose of 2024–25 COVID-19 vaccine.

‡ If the vaccination history includes 2024–25 Pfizer-BioNTech COVID-19 Vaccine, the dose(s) can be counted.

§ For additional information related to shared clinical decision-making see [Shared Clinical Decision-Making: Additional Doses of COVID-19 Vaccine for People Who Are Moderately or Severely Immunocompromised](#).

2024–2025 COVID-19 Vaccination Guidance

for People 6 Months of Age and Older



Table 2a. For people who **ARE** moderately or severely immunocompromised *Continued*

| 2024–25 Moderna COVID-19 Vaccine - CONTINUED | | | |
|---|---|--|---|
| Vaccine type: mRNA Do NOT use any previously available Moderna COVID-19 vaccine products. | | | |
| If current age is: | And the COVID-19 vaccination history is: | Then: | Administer: |
| 5 through 11 years of age*† | Unvaccinated (0 doses) | Give a 3-dose initial series. <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 4 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.‡ | 0.25 mL/25 µg in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection |
| | 1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) | Complete the series. <ul style="list-style-type: none"> • Dose 2 at least 4 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.‡ | |
| | 2 previous doses of any Moderna COVID-19 Vaccine (Doses 1 and 2) | Complete the series. <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.‡ | |
| | 3 or more previous doses any mRNA COVID-19 Vaccine, NOT including 1 dose of 2024–25 mRNA COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose, followed by 1 dose 6 months later.‡ | |
| | 3 or more previous doses of any mRNA COVID-19 Vaccine, INCLUDING ONLY 1 dose of 2024–25 mRNA COVID-19 Vaccine | Give 1 dose 6 months following the last dose of the 2024–25 COVID-19 vaccine.‡ | |
| | 4 or more previous doses of any mRNA COVID-19 vaccine, INCLUDING at least 2 doses of 2024–25 mRNA COVID-19 Vaccine | Additional dose(s) may be given using shared clinical decision-making at least 8 weeks after the last dose of 2024–25 COVID-19 vaccine.§ | |

* People 5 years of age and older who are moderately or severely immunocompromised should receive all doses of the initial series from the same manufacturer. For Moderna COVID-19 Vaccine, it is a 3-dose initial series. In the following circumstances, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication. For people who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:

- Dose 2 at least 4 weeks after Dose 1.
- Dose 3 at least 4 weeks after Dose 2.

† People should receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination. Children who turn:

- 5 years of age during the 3-dose initial series should complete the series with the age-appropriate dosage **0.25 mL /25 µg**. There is no dosage change.
- 12 years of age during the 3-dose initial series should complete the series with the age-appropriate dosage **0.5 mL/50 µg**.

‡ May be administered as soon as 8 weeks after the last dose of 2024–25 COVID-19 vaccine.

§ For additional information related to shared clinical decision-making see [Shared Clinical Decision-Making: Additional Doses of COVID-19 Vaccine for People Who Are Moderately or Severely Immunocompromised](#).

2024–2025 COVID-19 Vaccination Guidance

for People 6 Months of Age and Older



Table 2a. For people who **ARE** moderately or severely immunocompromised *Continued*

| 2024–25 Moderna COVID-19 Vaccine - CONTINUED | | | |
|---|---|--|--|
| Vaccine type: mRNA Do NOT use any previously available Moderna COVID-19 vaccine products. | | | |
| If current age is: | And the COVID-19 vaccination history is: | Then: | Administer: |
| 12 years and older *† | Unvaccinated (0 doses) | Give a 3-dose initial series. <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 4 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.‡ | 0.5 mL/50 µg in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection |
| | 1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) | Complete the series. <ul style="list-style-type: none"> • Dose 2 at least 4 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.‡ | |
| | 2 previous doses of any Moderna COVID-19 Vaccine (Doses 1 and 2) | Complete the series. <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.‡ | |
| | 3 or more previous doses of any COVID-19 Vaccine, NOT including 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose, followed by 1 dose 6 months later.‡ | |
| | 3 or more previous doses of any COVID-19 Vaccine, INCLUDING ONLY 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose 6 months following the last dose of the 2024–25 COVID-19 vaccine.‡ | |
| | 4 or more previous doses of any COVID-19 vaccine, INCLUDING at least 2 doses of any 2024–25 COVID-19 vaccine | Additional dose(s) may be given using shared clinical decision-making at least 8 weeks after the last dose of 2024–25 COVID-19 vaccine.§ | |

* People 5 years of age and older who are moderately or severely immunocompromised should receive all doses of the initial series from the same manufacturer. For Moderna COVID-19 Vaccine, it is a 3-dose initial series. In the following circumstances, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication. For people who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:

- Dose 2 at least 4 weeks after Dose 1.
- Dose 3 at least 4 weeks after Dose 2.

† People should receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination. Children who turn:

- 5 years of age during the 3-dose initial series should complete the series with the age-appropriate dosage **0.25 mL / 25 µg**. There is no dosage change.
- 12 years of age during the 3-dose initial series should complete the series with the age-appropriate dosage **0.5 mL/50 µg**.

‡ May be administered as soon as 8 weeks after the last dose of 2024–25 COVID-19 vaccine.

§ For additional information related to shared clinical decision-making see [Shared Clinical Decision-Making: Additional Doses of COVID-19 Vaccine for People Who Are Moderately or Severely Immunocompromised](#).

2024–2025 COVID-19 Vaccination Guidance

for People 6 Months of Age and Older



Table 2b. For people who **ARE** moderately or severely immunocompromised

| 2024–25 Pfizer-BioNTech COVID-19 Vaccine | | | |
|---|--|--|--|
| Vaccine type: mRNA Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products. | | | |
| If current age is: | And the COVID-19 vaccination history is: | Then: | Administer: |
| 6 months through 4 years* | Unvaccinated (0 doses) | Give a 3-dose initial series. <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 8 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.† | 0.3 mL/3 µg from a yellow-capped multidose vial Intramuscular (IM) injection |
| | 1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) | Complete the series. <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 8 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.† | |
| | 2 previous doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) | Complete the series. <ul style="list-style-type: none"> • Dose 3 at least 8 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.† | |
| | 3 or more previous doses of any Pfizer-BioNTech COVID-19 Vaccine, NOT including 1 dose of 2024–25 Pfizer-BioNTech COVID-19 vaccine‡ | Give 1 dose at least 8 weeks after the last dose, followed by 1 dose 6 months later.† | |
| | 3 or more previous doses of any Pfizer-BioNTech COVID-19 Vaccine, INCLUDING ONLY 1 dose of 2024–25 Pfizer-BioNTech COVID-19 vaccine‡ | Give 1 dose 6 months after the last dose of 2024–25 COVID-19 vaccine.† | |
| | 4 or more previous doses of any Pfizer-BioNTech COVID-19 Vaccine, INCLUDING at least 2 doses of 2024–25 Pfizer-BioNTech COVID-19 vaccine‡ | Additional dose(s) may be given using shared clinical decision-making at least 8 weeks after the last dose of 2024–25 COVID-19 vaccine.§ | |

* Children 6 months through 4 years of age who are moderately to severely immunocompromised should receive all COVID-19 vaccine doses from the same manufacturer. In the following circumstances, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication. If mRNA vaccines are administered from different manufacturers, a 3-dose initial series should be followed:

- Children who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:
 - Dose 2 at least 4 weeks after Dose 1.
 - Dose 3 at least 8 weeks after Dose 2.
- Children who received 2 doses of vaccine from different manufacturers, administer Dose 3 at least 8 weeks after Dose 2.

† May be administered as soon as 8 weeks after the last dose of 2024–25 COVID-19 vaccine.

‡ If the vaccination history includes 2024–25 Moderna COVID-19 Vaccine, the dose(s) can be counted.

§ For additional information related to shared clinical decision-making see [Shared Clinical Decision-Making: Additional Doses of COVID-19 Vaccine for People Who Are Moderately or Severely Immunocompromised](#).

2024–2025 COVID-19 Vaccination Guidance

for People 6 Months of Age and Older



Table 2b. For people who **ARE** moderately or severely immunocompromised *Continued*

2024–25 Pfizer-BioNTech COVID-19 Vaccine

Vaccine type: mRNA | Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products.

| If current age is: | And the COVID-19 vaccination history is: | Then: | Administer: |
|------------------------------|---|--|---|
| 5 through 11 years *† | Unvaccinated (0 doses) | Give a 3-dose initial series. <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.‡ | 0.3 mL/10 µg from a blue-capped single-dose vial Intramuscular (IM) injection |
| | 1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) | Complete the series. <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.‡ | |
| | 2 previous doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) | Complete the series. <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3.‡ | |
| | 3 or more previous doses of any mRNA COVID-19 vaccine, NOT including 1 dose of 2024–25 mRNA COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose, followed by 1 dose 6 months later.‡ | |
| | 3 or more previous doses of any mRNA COVID-19 vaccine, INCLUDING ONLY 1 dose of 2024–25 mRNA COVID-19 vaccine | Give 1 dose 6 months after the last dose of 2024–25 COVID-19 vaccine.‡ | |
| | 4 or more previous doses of any mRNA COVID-19 vaccine, INCLUDING at least 2 doses of 2024–25 mRNA COVID-19 vaccine | Additional dose(s) may be given using shared clinical decision-making at least 8 weeks after the last dose of 2024–25 COVID-19 vaccine.§ | |

* People 5 years of age and older who are moderately or severely immunocompromised should receive all doses of the initial series from the same manufacturer. For Pfizer-BioNTech COVID-19 Vaccine, it is a 3-dose initial series. In the following circumstances, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication. For people who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:

- Dose 2 at least 4 weeks after Dose 1.
- Dose 3 at least 4 weeks after Dose 2.

† People should receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination. Children who turn:

- 5 years of age during the 3-dose initial series should complete the series with the age-appropriate dosage **0.3 mL /10 µg**.
- 12 years of age during the 3-dose initial series should complete the series with the age-appropriate dosage **0.3 mL/30 µg**.

‡ May be administered as soon as 8 weeks after the last dose of 2024–25 COVID-19 vaccine.

§ For additional information related to shared clinical decision-making see [Shared Clinical Decision-Making: Additional Doses of COVID-19 Vaccine for People Who Are Moderately or Severely Immunocompromised](#).

2024–2025 COVID-19 Vaccination Guidance

for People 6 Months of Age and Older



Table 2b. For people who **ARE** moderately or severely immunocompromised *Continued*

| 2024–25 Pfizer-BioNTech COVID-19 Vaccine - CONTINUED | | | |
|---|--|--|--|
| Vaccine type: mRNA Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products. | | | |
| If current age is: | And the COVID-19 vaccination history is: | Then: | Administer: |
| 12 years and older ^{*†} | Unvaccinated (0 doses) | Give a 3-dose initial series. <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3. [‡] | 0.3 mL/30 µg in a manufacturer-filled syringe Intramuscular (IM) injection |
| | 1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) | Complete the series. <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3. [‡] | |
| | 2 previous doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) | Complete the series. <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2. Dose 4: Give 6 months after Dose 3. [‡] | |
| | 3 or more previous doses of any COVID-19 vaccine, NOT including 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose, followed by 1 dose 6 months later. [‡] | |
| | 3 or more previous doses of any COVID-19 vaccine, INCLUDING ONLY 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose 6 months after the last dose of 2024–25 COVID-19 vaccine. [‡] | |
| | 4 or more previous doses any COVID-19 vaccine, INCLUDING at least 2 doses of any 2024–25 COVID-19 vaccine | Additional dose(s) may be given using shared clinical decision-making at least 8 weeks after the last dose of 2024–25 COVID-19 vaccine. [§] | |

* People 5 years of age and older who are moderately or severely immunocompromised should receive all doses of the initial series from the same manufacturer. For Pfizer-BioNTech COVID-19 Vaccine, it is a 3-dose initial series. In the following circumstances, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication. For people who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:

- Dose 2 at least 4 weeks after Dose 1.
- Dose 3 at least 4 weeks after Dose 2.

† People should receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination. Children who turn:

- 5 years of age during the 3-dose initial series should complete the series with the age-appropriate dosage **0.3 mL/10 µg**.
- 12 years of age during the 3-dose initial series should complete the series with the age-appropriate dosage **0.3 mL/30 µg**.

‡ May be administered as soon as 8 weeks after the last dose of 2024–25 COVID-19 vaccine.

§ For additional information related to shared clinical decision-making see [Shared Clinical Decision-Making: Additional Doses of COVID-19 Vaccine for People Who Are Moderately or Severely Immunocompromised](#).

2024–2025 COVID-19 Vaccination Guidance

for People 6 Months of Age and Older



Table 2c. For people who **ARE** moderately or severely immunocompromised

| 2024–25 Novavax COVID-19 Vaccine Vaccine type: Protein subunit Do NOT use any previously available Novavax COVID-19 vaccine products. | | | |
|--|---|---|---|
| If current age is: | And the COVID-19 vaccination history is: | Then: | Administer:* |
| 12 years and older [†] | Unvaccinated (0 doses) | Give a 2-dose initial series. <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 3 weeks after Dose 1. Dose 3: Give 6 months after Dose 2. [‡] | 0.5 mL/5 µg in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection |
| | 1 previous dose of any Novavax COVID-19 Vaccine (Dose 1) | Complete the series. <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1. Dose 3: Administer 6 months after Dose 2. [‡] | |
| | 2 previous doses of 2024–25 Novavax COVID-19 Vaccine (Dose 1 and Dose 2) | Give 1 dose 6 months after the last dose of 2024–25 COVID-19 vaccine. [‡] | |
| | 2 or more previous doses of any Novavax COVID-19 Vaccine, NOT including 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose, followed by 1 dose 6 months later. [‡] | |
| | 2 or more previous doses of any Novavax COVID-19 Vaccine, INCLUDING ONLY 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose 6 months after the last dose of 2024–25 COVID-19 vaccine. [‡] | |
| | 3 or more previous doses of any Novavax COVID-19 Vaccine, INCLUDING at least 2 doses of any 2024–25 COVID-19 vaccine | Additional dose(s) may be given using shared clinical decision-making at least 8 weeks after the last dose of 2024–25 COVID-19 vaccine. [§] | |
| | 3 or more previous doses of any mRNA COVID-19 vaccine, NOT including 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose at least 8 weeks after the last dose, followed by 1 dose 6 months later. [‡] | |
| | 3 or more previous doses of any mRNA COVID-19 vaccine, INCLUDING ONLY 1 dose of any 2024–25 COVID-19 vaccine | Give 1 dose 6 months after the last dose of 2024–25 COVID-19 vaccine. [‡] | |
| | 3 or more previous doses of any mRNA COVID-19 vaccine, INCLUDING at least 2 doses of any 2024–25 COVID-19 vaccine | Additional dose(s) may be given using shared clinical decision-making at least 8 weeks after the last dose of 2024–25 COVID-19 vaccine. [§] | |

* Each 0.5 mL dose of Novavax contains 5 µg rS protein and 50 µg Matrix-M adjuvant.

† People 12 years of age and older who are moderately or severely immunocompromised should receive all doses of the initial series from the same manufacturer. For Novavax COVID-19 Vaccine, it is a 2-dose initial series. In the following circumstances, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication. Refer to [Clinical Guidance for COVID-19 Vaccination | CDC](#) for detailed guidance.

‡ May be administered as soon as 8 weeks after the last dose of 2024–25 COVID-19 vaccine.

§ For additional information related to shared clinical decision-making see [Shared Clinical Decision-Making: Additional Doses of COVID-19 Vaccine for People Who Are Moderately or Severely Immunocompromised](#).